255 related articles for article (PubMed ID: 15902297)
1. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Qi H; Ratnam M
Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
Wu Y; Guo SW
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
8. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
9. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Raffoux E; Chaibi P; Dombret H; Degos L
Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid for the treatment of myeloid malignancies.
Kuendgen A; Gattermann N
Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Wang AH; Wei L; Chen L; Zhao SQ; Wu WL; Shen ZX; Li JM
Ann Hematol; 2011 Aug; 90(8):917-31. PubMed ID: 21340723
[TBL] [Abstract][Full Text] [Related]
13. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
15. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
Poggi A; Catellani S; Garuti A; Pierri I; Gobbi M; Zocchi MR
Leukemia; 2009 Apr; 23(4):641-8. PubMed ID: 19151770
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2.
Britschgi A; Simon HU; Tobler A; Fey MF; Tschan MP
Br J Haematol; 2010 Apr; 149(1):55-64. PubMed ID: 20096012
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
Noack K; Mahendrarajah N; Hennig D; Schmidt L; Grebien F; Hildebrand D; Christmann M; Kaina B; Sellmer A; Mahboobi S; Kubatzky K; Heinzel T; Krämer OH
Arch Toxicol; 2017 May; 91(5):2191-2208. PubMed ID: 27807597
[TBL] [Abstract][Full Text] [Related]
18. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Siitonen T; Koistinen P; Savolainen ER
Leuk Res; 2005 Nov; 29(11):1335-42. PubMed ID: 15936818
[TBL] [Abstract][Full Text] [Related]
19. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Fredly H; Reikvam H; Gjertsen BT; Bruserud O
Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841
[TBL] [Abstract][Full Text] [Related]
20. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
Khanim FL; Bradbury CA; Arrazi J; Hayden RE; Rye A; Basu S; MacWhannell A; Sawers A; Griffiths M; Cook M; Freeman S; Nightingale KP; Grimwade D; Falciani F; Turner BM; Bunce CM; Craddock C
Br J Haematol; 2009 Feb; 144(3):332-41. PubMed ID: 19036090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
